mRNA vaccines: A promising platform for safer, more effective next-generation Orthopoxvirus immunization.

In recent work, Mucker et al. ¹ demonstrated that mRNA-1769 outperforms modified vaccinia Ankara (MVA), which has been deployed against recent mpox virus (MPXV) outbreaks, in reducing clinical symptoms and controlling viral replication, highlighting its potential as a scalable, safe, and effective next-generation platform for orthopoxvirus vaccination. In recent work, Mucker et al. demonstrated that mRNA-1769 outperforms vaccinia Ankara (MVA), which has been deployed against recent mpox virus (MPXV) outbreaks, in reducing clinical symptoms and controlling viral replication, highlighting its potential as a scalable, safe, and effective next-generation platform for orthopoxvirus vaccination. [ABSTRACT FROM AUTHOR]